Oleksandr Sverdlov, PhD
- 2Articles
- 29.3KReads1
- 2021–2025Active
- 21Collaborators
- 25Citations2
About
Oleksandr Sverdlov, PhD, affiliated with Novartis Pharmaceuticals Corporation in East Hanover, New Jersey, has published research focused on treatments for depression, including major depressive disorder and bipolar depression. His work includes clinical trials investigating the efficacy of Onfasprodil, a novel NR2B negative allosteric modulator, and the antidepressant citalopram in acute and preventive settings. Sverdlov's publications span from 2021 to 2025 and appear in Psychiatrist.com journals.
Publications
Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study
August 6, 2025
Efficacy of Citalopram Treatment in Bipolar Depression
January 12, 2021
1 Read counts for articles published before 2020 may include some non-human traffic.
2 Citation counts provided by Crossref.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.